This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (51)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

David M. Bamberger, MD; Stephen L. Dahl, PharmD

Arch Intern Med. 1992;152(3):554-557.

Abstract
• Study Objective.—
The purpose of this study was to assess and compare the impact of voluntary compliance and enforced compliance with institutional guidelines for initiating third-generation cephalosporin therapy.

Design.—
An audit of third-generation cephalosporin use during a 6-month period shortly after ceftriaxone and ceftazidime were added to the hospital formulary already containing cefotaxime was performed. During this period, compliance to institutional guidelines for initiating therapy was voluntary. A follow-up audit during a similar 6-month period was performed to assess compliance with institutional guidelines shortly after an enforcement policy was placed in effect. The results of these two audits were compared to assess usage patterns of these cephalosporins, compliance rates with institutional guidelines for initiating therapy, use of susceptibility testing to guide therapy, effect of use of these drugs on susceptibility patterns within the hospital, and third-generation cephalosporin costs during periods when institutional policy was unenforced and enforced.

Results.—
Only 24.2% of 66 courses of third-generation cephalosporins were initiated in compliance with institutional guidelines during the initial audit period. Susceptibility testing revealed an organism susceptible to a firstgeneration cephalosporin in 13 courses but in only six instances was a switch to the more narrow-spectrum antibiotic performed. At the time routine susceptibility testing to ceftazidime and ceftriaxone was instituted, 92% of Enterobacter cloacae were sensitive to ceftriaxone and 89% of Pseudomonas aeruginosa were sensitive to ceftazidime. Fifteen months later, when voluntary compliance to institutional policy was terminated, 70% of E cloacae were sensitive to ceftriaxone and 73% of P aeruginosa were sensitive to ceftazidime. During the last 6 months of this period, pharmacy expenditures totaled $50 000. The second audit revealed 85.4% of 48 courses of treatment complied with guidelines for initiating therapy. Since enforcement was instituted, sensitivity of E cloacae to ceftriaxone has risen to 88% and sensitivity of P aeruginosa to ceftazidime has increased to 80%. Pharmacy expenditures decreased to $23 000.

(Arch Intern Med. 1992;152:554-557)

Author Affiliations
From the Red IV Unit, University of Missouri-Kansas City, School of Medicine.

Footnotes
Accepted for publication October 29, 1991.

Reprint requests to the Red IV Unit, University of MissouriKansas City, School of Medicine, 2411 Holmes, Kansas City, MO 64108-2792 (Dr Bamberger).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Electronic antibiotic stewardship--reduced consumption of broad-spectrum antibiotics using a computerized antimicrobial approval system in a hospital setting
Buising et al.
J Antimicrob Chemother 2008;62:608-616.
ABSTRACT | FULL TEXT  

Antimicrobial Resistance among Gram-Negative Bacilli Causing Infections in Intensive Care Unit Patients in the United States between 1993 and 2004
Lockhart et al.
J. Clin. Microbiol. 2007;45:3352-3359.
ABSTRACT | FULL TEXT  

Electronic Surveillance System for Monitoring Surgical Antimicrobial Prophylaxis
Voit et al.
Pediatrics 2005;116:1317-1322.
ABSTRACT | FULL TEXT  

Antimicrobial Stewardship Programs in Health Care Systems
MacDougall and Polk
Clin. Microbiol. Rev. 2005;18:638-656.
ABSTRACT | FULL TEXT  

The successful introduction of a programme to reduce the use of iv ciprofloxacin in hospital
Weller
J Antimicrob Chemother 2002;49:827-830.
ABSTRACT | FULL TEXT  

The problem with cephalosporins
Dancer
J Antimicrob Chemother 2001;48:463-478.
ABSTRACT | FULL TEXT  

Implementation of Strategies to Control Antimicrobial Resistance
Murthy
Chest 2001;119 :405S-411S.
ABSTRACT | FULL TEXT  

Nosocomial Infections in the ICU: The Growing Importance of Antibiotic-Resistant Pathogens
Weber et al.
Chest 1999;115 :34S-41S.
ABSTRACT | FULL TEXT